Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis

NCT04434781
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

NCT04718181
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
risdiplam, omeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Results available

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

NCT05771428
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-552, Placebo for ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 6:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Fasting Predictors of OGTT and MMTT Response

NCT01998867
View directory record Official record
Conditions
Prediabetes, Hypertension, Obesity, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Health Diagnostic Laboratory, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi

NCT02333227
View directory record Official record
Conditions
Preterm Birth, Periodontal Disease, Caries, Dental
Interventions
Xylitol gum
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
10,069 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

NCT00224042
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

NCT01820442
View directory record Official record
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1 Interventional

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

NCT00216437
View directory record Official record
Conditions
Cancer of Liver
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2007 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

NCT01582295
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

NCT01809639
View directory record Official record
Conditions
Concussion
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 44 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

NCT00977483
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Thioctic Acid, Placebo
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 30, 2026, 6:20 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159
View directory record Official record
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 30, 2026, 6:20 PM EDT
Not listed Phase 2 Interventional

Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia

NCT01302288
View directory record Official record
Conditions
Achalasia
Interventions
Per oral endolumenal myotomy
Procedure
Lead sponsor
The Oregon Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

NCT02921386
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770
View directory record Official record
Conditions
Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
Interventions
Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

NCT03366142
View directory record Official record
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Study Evaluating TMI-005 in Active Rheumatoid Arthritis

NCT00095342
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TMI-005
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
4
States / cities
Indianapolis, Indiana • Syracuse, New York • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1 Interventional

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor, Metastatic Solid Tumor, ALK Gene Mutation
Interventions
TPX-0131
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

NCT04120883
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 30, 2026, 6:20 PM EDT